MedTrace Logo

[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy

NCT04870580 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-11-18

No results posted yet for this study

Summary

\[18F\]fluorodopa (3, 4-dihydroxy-6-\[18F\]fluoro-L-phenylalanine/ FDOPA) is an amino acid PET tracer originally developed for brain imaging in patients with movement disorders but has been found to be useful in brain tumour imaging. \[18F\]fluorodopa has been demonstrated to be predominantly transported by the L-type amino acid transporter without significant uptake into surrounding normal brain parenchyma with the exception of the basal ganglia. Assessing the feasibility of performing PET guided histopathology in a single and multi-site setting will be crucial in order to use PET as a planning tool for brain biopsy to detect high-grade transformation in low-grade gliomas.

Conditions

Interventions

DIAGNOSTIC_TEST

Fluorodopa PET tracer

PET/CT scan using fluorodopa tracer

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Geoffrey Higgins · University College, London

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04870580 on ClinicalTrials.gov